CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, Louisa McIlwaine et al.|Blood Advances|2023Cited by 32
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of MyelofibrosisAdrián Mosquera-Orgueira, Manuel Pérez‐Encinas, Alberto Hernández‐Sánchez et al.|HemaSphere|2022Cited by 30
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of MyelofibrosisJuan Carlos Hernández‐Boluda, Irene Pastor‐Galán, Eduardo Arellano‐Rodrigo et al.|British Journal of Haematology|2022Cited by 16
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of MyelofibrosisIrene Pastor‐Galán, Francisco Cervantes, Juan Carlos Hernández‐Boluda et al.|Medicina Clínica (English Edition)|2020Cited by 12
Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosisAdrián Mosquera Orgueira, Eduardo Arellano‐Rodrigo, Marta Garrote et al.|HemaSphere|2024Cited by 6